Cancer drug maker gave last-minute discount deal to HSE
The HSE declined to disclose the price reduction secured
The HSE secured a discount on the cancer medicine Pembrolizumab, after the manufacturer offered a last-minute price reduction.
In a letter to health minister Simon Harris, HSE director general Tony O’Brien said pharmaceutical company MSD had offered “revised commercial terms” in May.
In his June 2 letter to Harris, O’Brien confirmed that the HSE directorate had approved funding of the medicine, dubbed ‘Pembro’, which is used to treat advanced melanoma –...
Subscribe from just €1 for the first month!
What's Included
With any subscription you will have access to
-
Unlimited multi-device access to our iPad, iPhone and Android Apps
-
Unlimited access to our eReader library
-
Exclusive daily insight and opinion seven days a week
-
Create alerts to never miss a subject that matters to you
-
Get access to exclusive offers for subscribers on gifts and experiences
-
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Related Stories
ESRI predicts health spending will rise due to growing and ageing population
Increased demand for non-hospital care and price hikes for high-tech medicines are among the factors expected to push up costs
Global tobacco firm lobbies government to keep e-cigarettes free of excise duty
JTI, which owns the Silk Cut and Camel brands, says e-cigarettes offer an ‘alternative to smoking’ and should remain excise-free at the next budget
Children prescribed adult doses of drugs at Kerry mental health centre
Parents of one child have launched legal proceedings against the HSE and an investigation is under way over treatment of up to 400 children between 2016 and 2020
Patients with rare diseases urge Dáil to pass law on orphan drugs
Three years after a bill on the issue was first proposed, patients say they are tired of agonising delays to accessing life-changing treatments
